Catalyst Wire Dossier Catalyst Wire Dossier

Duvortuxizumab

duvortuxizumab · Janssen Research & Development, LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Duvortuxizumab, covering 2025-02-03 to 2025-02-03. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma [Phase 1]

See pricing